<?xml version="1.0"?>
<rss version="2.0">
   <channel>
      <title>HNN215 Week 3 12pm by </title>
      <link>https://padlet.com/sarahd59/zlm8kmu7h9d5e8e0</link>
      <description>Management of patients experiencing cardiovascular symptoms (1)</description>
      <language>en-us</language>
      <pubDate>2023-07-23 07:40:20 UTC</pubDate>
      <lastBuildDate>2026-01-25 21:24:56 UTC</lastBuildDate>
      <webMaster>hello@padlet.com</webMaster>
      <image>
         <url></url>
      </image>
      <item>
         <title>Significant drug-drug interactions???</title>
         <author>sarahd59</author>
         <link>https://padlet.com/sarahd59/zlm8kmu7h9d5e8e0/wish/2649670786</link>
         <description><![CDATA[<div>How / why does it occur?<br>What are they and what signs and symptoms would we see?<br>What do we as nurses do;<br>- prevent and/ or manage these?</div>]]></description>
         <enclosure url="https://padlet-uploads.storage.googleapis.com/1978789677/243ff23c222b0bfd8bef6b8f051ce823/image.png" />
         <pubDate>2023-07-23 07:40:20 UTC</pubDate>
         <guid>https://padlet.com/sarahd59/zlm8kmu7h9d5e8e0/wish/2649670786</guid>
      </item>
      <item>
         <title>Compare and contrast the significant risks for each of the drug classes</title>
         <author>sarahd59</author>
         <link>https://padlet.com/sarahd59/zlm8kmu7h9d5e8e0/wish/2649670787</link>
         <description><![CDATA[<div>What were your significant risks? Why are they significant?<br>Do you understand the MoA of how the patient might develop the risk?<br>Did you need to go and look them up again? </div>]]></description>
         <enclosure url="" />
         <pubDate>2023-07-23 07:40:20 UTC</pubDate>
         <guid>https://padlet.com/sarahd59/zlm8kmu7h9d5e8e0/wish/2649670787</guid>
      </item>
      <item>
         <title>Part 2???</title>
         <author>sarahd59</author>
         <link>https://padlet.com/sarahd59/zlm8kmu7h9d5e8e0/wish/2649670788</link>
         <description><![CDATA[<div>This will be added once we get to it :)</div>]]></description>
         <enclosure url="" />
         <pubDate>2023-07-23 07:40:20 UTC</pubDate>
         <guid>https://padlet.com/sarahd59/zlm8kmu7h9d5e8e0/wish/2649670788</guid>
      </item>
      <item>
         <title>Consider???</title>
         <author>sarahd59</author>
         <link>https://padlet.com/sarahd59/zlm8kmu7h9d5e8e0/wish/2649670789</link>
         <description><![CDATA[<div><strong><mark>Note: Always consider:<br>Is there anything in the patient's condition/ past history that may increase the risks?</mark></strong></div>]]></description>
         <enclosure url="" />
         <pubDate>2023-07-23 07:40:20 UTC</pubDate>
         <guid>https://padlet.com/sarahd59/zlm8kmu7h9d5e8e0/wish/2649670789</guid>
      </item>
      <item>
         <title>Group 4</title>
         <author>sarahd59</author>
         <link>https://padlet.com/sarahd59/zlm8kmu7h9d5e8e0/wish/2649670790</link>
         <description><![CDATA[]]></description>
         <enclosure url="" />
         <pubDate>2023-07-23 07:40:20 UTC</pubDate>
         <guid>https://padlet.com/sarahd59/zlm8kmu7h9d5e8e0/wish/2649670790</guid>
      </item>
      <item>
         <title>Group 5</title>
         <author>sarahd59</author>
         <link>https://padlet.com/sarahd59/zlm8kmu7h9d5e8e0/wish/2649670791</link>
         <description><![CDATA[]]></description>
         <enclosure url="" />
         <pubDate>2023-07-23 07:40:20 UTC</pubDate>
         <guid>https://padlet.com/sarahd59/zlm8kmu7h9d5e8e0/wish/2649670791</guid>
      </item>
      <item>
         <title>Group 2</title>
         <author>sarahd59</author>
         <link>https://padlet.com/sarahd59/zlm8kmu7h9d5e8e0/wish/2649670792</link>
         <description><![CDATA[]]></description>
         <enclosure url="" />
         <pubDate>2023-07-23 07:40:20 UTC</pubDate>
         <guid>https://padlet.com/sarahd59/zlm8kmu7h9d5e8e0/wish/2649670792</guid>
      </item>
      <item>
         <title>Group 3</title>
         <author>sarahd59</author>
         <link>https://padlet.com/sarahd59/zlm8kmu7h9d5e8e0/wish/2649670793</link>
         <description><![CDATA[]]></description>
         <enclosure url="" />
         <pubDate>2023-07-23 07:40:20 UTC</pubDate>
         <guid>https://padlet.com/sarahd59/zlm8kmu7h9d5e8e0/wish/2649670793</guid>
      </item>
      <item>
         <title>Case Scenario</title>
         <author>sarahd59</author>
         <link>https://padlet.com/sarahd59/zlm8kmu7h9d5e8e0/wish/2649670794</link>
         <description><![CDATA[]]></description>
         <enclosure url="https://padlet-uploads.storage.googleapis.com/1978789677/35c5ac5a8706da9a51b2bc6965aff551/image.png" />
         <pubDate>2023-07-23 07:40:20 UTC</pubDate>
         <guid>https://padlet.com/sarahd59/zlm8kmu7h9d5e8e0/wish/2649670794</guid>
      </item>
      <item>
         <title>Scenario continued</title>
         <author>sarahd59</author>
         <link>https://padlet.com/sarahd59/zlm8kmu7h9d5e8e0/wish/2649670795</link>
         <description><![CDATA[]]></description>
         <enclosure url="https://padlet-uploads.storage.googleapis.com/1978789677/5b1567bb619a0df10977b9403f1eaaee/image.png" />
         <pubDate>2023-07-23 07:40:20 UTC</pubDate>
         <guid>https://padlet.com/sarahd59/zlm8kmu7h9d5e8e0/wish/2649670795</guid>
      </item>
      <item>
         <title></title>
         <author>sarahd59</author>
         <link>https://padlet.com/sarahd59/zlm8kmu7h9d5e8e0/wish/2649670796</link>
         <description><![CDATA[]]></description>
         <enclosure url="https://padlet-uploads.storage.googleapis.com/1978789677/3a149730a6730ccc2eac23b380419082/HNN215_week_3_NIMC_2023.pdf" />
         <pubDate>2023-07-23 07:40:20 UTC</pubDate>
         <guid>https://padlet.com/sarahd59/zlm8kmu7h9d5e8e0/wish/2649670796</guid>
      </item>
      <item>
         <title>Group 1</title>
         <author>sarahd59</author>
         <link>https://padlet.com/sarahd59/zlm8kmu7h9d5e8e0/wish/2649670797</link>
         <description><![CDATA[<div><strong>Metoprolol<br>Class: </strong>Beta-Blocker<strong><br>MOA: </strong>Blocks beta receptors in the heart and around the body to reduce HR, BP and cardiac contractility. <strong><br>Indications for use: <br></strong>- Hypertension<br>- Angina<br>- Tachyarrhythmias<br>- Myocardial Infarction<br>- Prevention of migraine. <strong><br>Signs &amp; symptoms: </strong>bradycardia, hypotension, alteration of BGL's, nausea, diarrhoea, dizziness, worsening of heart failure and fatigue. <strong><br>How to identify, prevent or manage risks/nursing considerations: <br></strong>- Monitor ECG and BP continuously during IV administration.&nbsp;<br>- Ensure pt.'s are haemodynamically stable.&nbsp;<br>- Start with a low dose and gradually increase to the highest tolerable maintenance dose.&nbsp;<br><br>--&gt; Drug to drug interactions: some Calcium channel blockers.&nbsp;<br><br></div>]]></description>
         <enclosure url="" />
         <pubDate>2023-07-23 07:40:20 UTC</pubDate>
         <guid>https://padlet.com/sarahd59/zlm8kmu7h9d5e8e0/wish/2649670797</guid>
      </item>
      <item>
         <title></title>
         <author>sarahd59</author>
         <link>https://padlet.com/sarahd59/zlm8kmu7h9d5e8e0/wish/2649670798</link>
         <description><![CDATA[]]></description>
         <enclosure url="https://padlet-uploads.storage.googleapis.com/1978789677/a9370c30f0e9dd5c9a707fd5dd3e14dd/IV_Orders_week_3_2023.pdf" />
         <pubDate>2023-07-23 07:40:20 UTC</pubDate>
         <guid>https://padlet.com/sarahd59/zlm8kmu7h9d5e8e0/wish/2649670798</guid>
      </item>
      <item>
         <title>Group 2</title>
         <author>sarahd59</author>
         <link>https://padlet.com/sarahd59/zlm8kmu7h9d5e8e0/wish/2649670799</link>
         <description><![CDATA[<div><strong>Amlodipine<br>Class: </strong>Calcium channel blockers - Dihydropyridines <strong><br>MOA: </strong>blocking the voltage-dependent L-type calcium channels, thereby inhibiting the initial influx of calcium<strong><br>Indications for use; </strong>works on cardiac smooth muscle to reduce arterial blood pressure and angina<strong><br>Signs &amp; Symptoms: </strong>headache-intracranial pressure, hypotension,dizziness, syncope, reflex tachycardia due to hypertension <strong><br>How to identify, prevent or manage risks/nursing considerations: </strong>adapt the environment to reduce the risk of falls, monitor blood pressure and heart rate (ECG), encourage good fluid and food intake, adjust the dosage if required (communicate with doctor), <strong><br></strong><br></div>]]></description>
         <enclosure url="" />
         <pubDate>2023-07-23 07:40:20 UTC</pubDate>
         <guid>https://padlet.com/sarahd59/zlm8kmu7h9d5e8e0/wish/2649670799</guid>
      </item>
      <item>
         <title>Group 3</title>
         <author>sarahd59</author>
         <link>https://padlet.com/sarahd59/zlm8kmu7h9d5e8e0/wish/2649670800</link>
         <description><![CDATA[<div><strong>Amiodarone<br>Class:<br>MOA:<br>Indications for use:<br>Signs &amp; symptoms:<br>How to identify, prevent or manage risks/nursing considerations:</strong></div>]]></description>
         <enclosure url="" />
         <pubDate>2023-07-23 07:40:20 UTC</pubDate>
         <guid>https://padlet.com/sarahd59/zlm8kmu7h9d5e8e0/wish/2649670800</guid>
      </item>
      <item>
         <title>Group 4</title>
         <author>sarahd59</author>
         <link>https://padlet.com/sarahd59/zlm8kmu7h9d5e8e0/wish/2649670801</link>
         <description><![CDATA[<div>T<strong>emazepam&nbsp;<br>Class: benzodiazepines(sedative)<br>MOA: inhibits the effect of GABA throughout the CNS<br>results in anxiolytic, sedative, hypnotic,muscle relaxant, and antiepileptic effects<br><br>Indications for use:<br>short term treatment of insomnia<br><br>Signs &amp; symptoms:<br>common:<br>drowsiness, sedation, effects on vision, tiredness, light headed ness, dried mouth, slurred speech, dependance<br><br>How to identify, prevent, or manage risks/nursing considerations:<br><br>life-threatening breathing problem<br>sedation and coma<br>compromise respiratory drive&nbsp;<br>struggle to swallow<br>dependence-physical and psychological , tolerance and misuse&nbsp;<br>renal impairment<br>contraindicated in hepatic impairment<br>increased risk of falls and over-sedation<br><br>practice point:<br>short-term (2-4 weeks) or intermittent use<br>withdrawal:<br>suddenly stopping,</strong></div>]]></description>
         <enclosure url="" />
         <pubDate>2023-07-23 07:40:20 UTC</pubDate>
         <guid>https://padlet.com/sarahd59/zlm8kmu7h9d5e8e0/wish/2649670801</guid>
      </item>
      <item>
         <title>Group 5</title>
         <author>sarahd59</author>
         <link>https://padlet.com/sarahd59/zlm8kmu7h9d5e8e0/wish/2649670802</link>
         <description><![CDATA[<div><strong>Potassium/Magnesium<br>Class: Potassium is a mineral and a electrolyte, meaning it conduct electricity.<br><br><br>MOA: <br></strong>Magnesium plays an important role in the regulation of several bodily processes including blood pressure, insulin metabolism, muscular contraction, vasomotor tone, cardiac excitability, nerve transmission and neuromuscular conduction.<strong><br><br><br></strong>&nbsp; <strong>Indications for use:<br><br></strong>Magnesium supports essential muscle and heart functioning&nbsp; potassium benefits heart functioning by helping to control the activity of the heart muscle.<strong><br><br>Signs &amp; symptoms:<br><br></strong><br></div><ul><li>Constipation.</li><li>Feeling of skipped heart beats or palpitations.</li><li>Fatigue.</li><li>Muscle damage.</li><li>Tingling or numbness.</li><li>weakness.</li><li>feeling tired.</li><li>muscle cramps.</li><li>confusion.</li><li>constipation.</li><li>an abnormal heart rhythm (arrhythmia) – skipped heartbeats or an irregular heartbeat.</li><li>tingling or numbness.</li><li>increased urination</li></ul><div><br></div><div><strong>How to identify, prevent or manage risks/nursing considerations:<br><br></strong><br></div><ul><li>Monitor blood potassium levels.</li><li>Check renal function.&nbsp;</li><li>Review the patient's current medications.</li><li>Review the patient's diet.</li><li>Include or limit potassium in the diet.</li><li>Administer prescribed potassium with precautions.&nbsp;</li><li>Monitor strict intake and output.</li></ul><div><strong><br><br></strong><br></div>]]></description>
         <enclosure url="" />
         <pubDate>2023-07-23 07:40:20 UTC</pubDate>
         <guid>https://padlet.com/sarahd59/zlm8kmu7h9d5e8e0/wish/2649670802</guid>
      </item>
      <item>
         <title>Loading doses</title>
         <author>sarahd59</author>
         <link>https://padlet.com/sarahd59/zlm8kmu7h9d5e8e0/wish/2649670803</link>
         <description><![CDATA[]]></description>
         <enclosure url="https://padlet-uploads.storage.googleapis.com/1978789677/8b2a7bd488b20e9a33495e81c9ec9880/image.png" />
         <pubDate>2023-07-23 07:40:20 UTC</pubDate>
         <guid>https://padlet.com/sarahd59/zlm8kmu7h9d5e8e0/wish/2649670803</guid>
      </item>
      <item>
         <title>Additional considerations</title>
         <author>sarahd59</author>
         <link>https://padlet.com/sarahd59/zlm8kmu7h9d5e8e0/wish/2649670804</link>
         <description><![CDATA[<div>Something to consider : do we need to think about the patient's underlying condition such as renal function/ liver function when giving a loading dose? Or body weight? If so why??</div>]]></description>
         <enclosure url="http://image.slideserve.com/275846/loading-dose-l.jpg" />
         <pubDate>2023-07-23 07:40:20 UTC</pubDate>
         <guid>https://padlet.com/sarahd59/zlm8kmu7h9d5e8e0/wish/2649670804</guid>
      </item>
      <item>
         <title>Group 1</title>
         <author>sarahd59</author>
         <link>https://padlet.com/sarahd59/zlm8kmu7h9d5e8e0/wish/2649670805</link>
         <description><![CDATA[]]></description>
         <enclosure url="" />
         <pubDate>2023-07-23 07:40:20 UTC</pubDate>
         <guid>https://padlet.com/sarahd59/zlm8kmu7h9d5e8e0/wish/2649670805</guid>
      </item>
      <item>
         <title>Group 4 </title>
         <author></author>
         <link>https://padlet.com/sarahd59/zlm8kmu7h9d5e8e0/wish/2649938763</link>
         <description><![CDATA[<div><strong>Temazepam </strong><br><strong>Class:</strong> Benzodiazepines <br><strong>MOA:</strong> Benzodiazepines increases the affinity of GABA throughout the CNS, resulting in anxiolytic, sedative, hypnotic, muscle relaxant and antiepileptic effects.</div><div><strong><em>Indications:</em></strong> Insomnia, seizures ( short term use)</div><div><strong>Signs &amp; Symptoms:</strong> dizziness, worsening depression, confusion, anxiety, memory loss, hallucinations, behavioural changes<br><strong>Drug-Drug interactions: </strong>antihistamines, antipsychotics, opioids, hypnotics <br><strong>How to identify, prevent/ manage risks/ nursing considerations: </strong>reserve for short-term (2–4 weeks) or intermittent use only<br>Drug withdrawal chart <br>Sedation chart <br>Nursing education - no alcohol  <strong><br><br> </strong><br><br><br></div>]]></description>
         <enclosure url="" />
         <pubDate>2023-07-24 02:41:24 UTC</pubDate>
         <guid>https://padlet.com/sarahd59/zlm8kmu7h9d5e8e0/wish/2649938763</guid>
      </item>
      <item>
         <title>Group3- Amiodarone</title>
         <author>s223288682</author>
         <link>https://padlet.com/sarahd59/zlm8kmu7h9d5e8e0/wish/2649940424</link>
         <description><![CDATA[<div>Drug class- Class is lll Anti-arrhythmic&nbsp;<br><br>MOA- It blocks potassium currents that cause repolarization of the heart muscle during the third phase of the cardiac action potential.<br><br>Indications-used for the treatment of recurrent hemodynamically unstable ventricular tachycardia and recurrent ventricular fibrillation, high risk of sudden cardiac arrest.<br><br>Side effects- cough, dizziness, fever, tingling of fingers and hands, painful breathing, fainting.<br><br>Interactions-&nbsp; Warfrin, diltiazem, disopyramide, atorvastatin, fluvastatin<br><br>Nursing considerations-&nbsp; Not recommended in breastfeeding women<br>- Monitor blood pressure<br>-Check for hypersensitivity reactions<br>-Check respiration rate because that drug causes pulmonary toxicity.<br><br><br><br><br></div>]]></description>
         <enclosure url="" />
         <pubDate>2023-07-24 02:43:31 UTC</pubDate>
         <guid>https://padlet.com/sarahd59/zlm8kmu7h9d5e8e0/wish/2649940424</guid>
      </item>
   </channel>
</rss>
